Mosaic Biosciences is advancing a fundamentally new class of synthetic materials to support native tissue regeneration. With its proprietary platform technology, Mosaic expects to significantly impact the field of tissue regeneration, including applications in wound healing, bone regeneration, cartilage repair, stem cell therapy, and dermal fillers. Mosaic’s products are based on a novel and patented technology platform that can be used to develop synthetic extracellular matrices for support of natural tissue regeneration. These 3-dimensional scaffolds are designed to have the specific biophysical and biochemical properties necessary to support native tissue structures and promote new tissue formation.

from http://www.mosaicbio.com/

Patents 15show all

  • 6
    A61K - Preparations for medical, dental, or toilet purposes
  • 4
    A61L - Methods or apparatus for sterilising materials or objects in general
  • 4
    C08L - Compositions of macromolecular compounds
  • 2
    C07K - Peptides
  • 2
    C12N - Microorganisms or enzymes
  • 2
    C12Y - Enzymes

SEC Filings show all


2
D

Contact Information

Boulder, CO
United States

Overview

Total FundingEmployeesLast Funding DateStatus
$3,274,00011-502014-02-10Operating

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2014-02-10$2,274,000Series Unknown
2011-11-08$1,000,000Series AHigh Country Venture, Morgenthaler Ventures, HealthCare Ventures

Key Executives

  • Martin Stanton
    Executive Officer, Director
  • Nassim Usman
    Director
  • Augustine Lawlor
    Director
  • Mark Lupa
    Director
  • Guy Katsav
    Director